This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
DaVita HealthCare (DVA) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
The latest trading day saw DaVita HealthCare (DVA) settling at $162.36, representing a +0.22% change from its previous close.
DaVita HealthCare (DVA) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
DaVita HealthCare (DVA) closed the most recent trading day at $152.69, moving +0.77% from the previous trading session.
DaVita HealthCare (DVA) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
The latest trading day saw DaVita HealthCare (DVA) settling at $151.53, representing a -0.84% change from its previous close.
Compelling Reasons for Investors to Hold on to Centene Stock
by Zacks Equity Research
CNC remains well-poised for growth on the back of an expanding customer base, improved premiums, strategic acquisitions and commendable cash reserves.
Should Value Investors Buy DaVita (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DaVita HealthCare (DVA) Stock Moves -0.16%: What You Should Know
by Zacks Equity Research
DaVita HealthCare (DVA) closed at $149.55 in the latest trading session, marking a -0.16% move from the prior day.
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $155.06, denoting a +1.33% change from the preceding trading day.
DaVita Stock Gains 40.1% Year to Date: What's Behind the Rally?
by Zacks Equity Research
Strength in kidney care services and expansion into international markets raise optimism for DVA stock.
DaVita HealthCare (DVA) Stock Moves -0.55%: What You Should Know
by Zacks Equity Research
DaVita HealthCare (DVA) reachead $146.76 at the closing of the latest trading day, reflecting a -0.55% change compared to its last close.
DaVita Stock Declines After Q3 Earnings Miss Estimates, Margins Up
by Zacks Equity Research
DVA's robust Dialysis patient service revenues drives its third-quarter performance.
DaVita HealthCare (DVA) Q3 Earnings Miss Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of -6.16% and 1.29%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
DVA Q3 Estimates Unchanged Before Earnings: How to Play the Stock?
by Debanjana Dey
Improvement in RPT is likely to have boosted DaVita's top line in the third quarter.
DaVita HealthCare (DVA) Stock Moves -0.23%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $162.78, denoting a -0.23% change from the preceding trading day.
DaVita HealthCare (DVA) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
DaVita HealthCare (DVA) concluded the recent trading session at $163.16, signifying a +1% move from its prior day's close.
AVTR Stock Flat Following the Close of Divestiture Deal With Audax
by Zacks Equity Research
Avantor closes its deal with Audax to divest its clinical services business.
Cencora Rallies 14.7% Year to Date: What's Driving the Stock?
by Zacks Equity Research
COR is gaining traction from the robust U.S. Healthcare Solutions segment, which raises optimism about the stock.
Henry Schein Stock Gains From Dental Business Expansion Amid Macro Woe
by Zacks Equity Research
Henry Schein strategically sets up distribution centers worldwide to better serve customers and increase its operating efficiency.
CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch
by Zacks Equity Research
Charles River launches Retrogenix Non-Human Protein Library to provide early insights into how therapeutics interact with non-human protein targets in vitro.
GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa
by Zacks Equity Research
Glaukos announces positive second Phase 3 confirmatory pivotal trial for Epioxa.
Here's Why You Should Retain Accuray Stock in Your Portfolio Now
by Zacks Equity Research
ARAY's solid product demand and revenue growth raise optimism about the stock.
BRKR Stock to Gain From Newly Formed Bruker Spatial Biology Division
by Zacks Equity Research
Bruker announces the formation of the new Bruker Spatial Biology division.
Encompass Health Corporation (EHC) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Encompass Health (EHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Retain PDCO Stock in Your Portfolio for Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies on the back of its broad product line.
DaVita HealthCare (DVA) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
In the most recent trading session, DaVita HealthCare (DVA) closed at $164.82, indicating a +0.15% shift from the previous trading day.
Catalent Stock Flat Following the Sell Agreement With Ardena
by Zacks Equity Research
CTLT announces an agreement to sell its oral solids development and manufacturing facility in Somerset to Ardena.